Sign In
Buy MNLO
$0.555
+0 (+0%)
At Close: Aug 17, 2022
Menlo (MNLO) in Focus: Stock Moves 9.9% Higher
12:53pm, Friday, 24'th Apr 2020
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ™ and, if approved in the U.S., FMX103 and FCD105 in the Greater China
Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test
08:52pm, Tuesday, 21'st Apr 2020
A Cara Therapeutics drug developed to treat the severe itching experienced by patients receiving hemodialysis has met the main goal of a second late-stage
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
01:12pm, Friday, 10'th Apr 2020
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences
7 Penny Stocks To Buy with Massive Upside Potential
04:49pm, Wednesday, 08'th Apr 2020
There could be a reason these penny stocks trade for under $5, but returns could be monstrous with even minor share price appreciation.
The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
11:53am, Wednesday, 08'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Masimo C
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporat
H.C. Wainwright Thinks Menlo Therapeutics’ Stock is Going to Recover
11:13am, Tuesday, 07'th Apr 2020
H.C. Wainwright analyst
Oren Livnat
maintained a
Buy
rating on Menlo Therapeutics (
MNLO
–
Research Report
) today and set a price target of
$2.00
. The company’s shares closed last Monday at $1.4
Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends
09:45pm, Monday, 06'th Apr 2020
An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on
Fly Intel: Pre-market Movers CODX;AXSM;SEAS;TEN;XBIT;TSLA;SMPL;DGLY;DAL;TDY;MNLO
01:38pm, Monday, 06'th Apr 2020
Fly Intel: Pre-market Movers CODX AXSM SEAS TEN XBIT TSLA SMPL DGLY DAL TDY MNLO
Patients were randomized 1:1 to either serlopitant 5mg or placebo treatment. In the merger, Foamix shareholders received 0.5924 shares of Menlo common stock for each share of Foamix held at the closi
Menlo Therapeutics Inc (NASDAQ:MNLO) Shares Sold by Janus Henderson Group PLC
09:50am, Monday, 06'th Apr 2020
Janus Henderson Group PLC decreased its stake in Menlo Therapeutics Inc (NASDAQ:MNLO) by 9.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
06:03pm, Sunday, 05'th Apr 2020
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts...
Menlo Therapeutics announces settlement to conclude Finacea Foam litigation MNLO;FOMX;TEVA;PRGO
12:19pm, Thursday, 02'nd Apr 2020
Menlo Therapeutics announces settlement to conclude Finacea Foam litigation MNLO FOMX TEVA PRGO
MarineMax withdraws FY20 guidance amid COVID-19 uncertainties HZO
12:08pm, Thursday, 02'nd Apr 2020
MarineMax withdraws FY20 guidance amid COVID-19 uncertainties HZO
